CN114767839A - 一种纳米复合物及应用 - Google Patents
一种纳米复合物及应用 Download PDFInfo
- Publication number
- CN114767839A CN114767839A CN202210350622.1A CN202210350622A CN114767839A CN 114767839 A CN114767839 A CN 114767839A CN 202210350622 A CN202210350622 A CN 202210350622A CN 114767839 A CN114767839 A CN 114767839A
- Authority
- CN
- China
- Prior art keywords
- catalase
- cat
- peg
- sepsis
- nhs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002114 nanocomposite Substances 0.000 title claims abstract description 12
- 102000016938 Catalase Human genes 0.000 claims abstract description 36
- 108010053835 Catalase Proteins 0.000 claims abstract description 36
- 206010040047 Sepsis Diseases 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 108010051874 catalase-polyethylene glycol Proteins 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 14
- 238000001727 in vivo Methods 0.000 abstract description 10
- 102000004127 Cytokines Human genes 0.000 abstract description 8
- 108090000695 Cytokines Proteins 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 229910001868 water Inorganic materials 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 230000008810 intracellular oxidative stress Effects 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 description 14
- 239000003642 reactive oxygen metabolite Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241001455191 Dasyurus albopunctatus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Manufacturing & Machinery (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Biochemistry (AREA)
Abstract
本发明涉及一种纳米复合物及应用,属于医药技术领域。本发明通过mPEG‑NHS修饰过氧化氢酶(Catalase CAT)获到高活力保留的CAT‑PEG,具有良好的水溶性,体内长循环性及生物相容性。与天然过氧化氢酶相比,更有助于缓解细胞内氧化应激,调节细胞因子的产生,减轻由活性氧引起的损伤。为脓毒症的药物应用提供新的途径。
Description
技术领域
本发明涉及一种纳米复合物及应用,属于医药技术领域。
背景技术
脓毒症是机体对感染的反应失调而导致危及生命的器官功能障碍。相关研究表明每年全球脓毒症患者数>1900万,其中有600万患者死亡,病死率超过25%,发达国家的脓毒症死亡率在20%以上,超过心肌梗死的死亡率。存活的患者中约有300万人存在认知功能障碍,严重影响生活质量。65岁以上人群、婴儿、免疫功能低下患者和慢性病患者(自身免疫性疾病、肿瘤、肾脏疾病、肺部疾病等)对脓毒症的易感性最高。脓毒症休克也是当前新冠病毒(COVID-19)肺炎重症患者常见的临床表现之一。目前脓毒症药物治疗主要包括液体治疗(晶体液、白蛋白),抗菌药物,血管活性药物(去甲肾上腺素),糖皮质激素等。由于个体差异大、老龄化、抗菌药物耐药性急剧增加等因素,脓毒症的发病率和死亡率居高不下,急需开发脓毒症的治疗药物来满足临床需求。
尽管脓毒症的发病机理极为复杂,但大量研究表明,脓毒症尤其感染性休克时,机体会产生大量的以过氧化氢为代表的活性氧(Reactive Oxygen Species ROS),消耗大量抗氧化成分,此同时由于缺血缺氧导致合成抗氧化成分所需要的酶原料缺乏,难以充分合成机体抗氧化成分,或合成这些抗氧化成分的细胞受损、功能障碍,导致机体ROS清除能力下降,H2O2可能局部或系统地积累,H2O2与含硫残基(半胱氨酸和蛋氨酸)氧化蛋白质,并与过渡金属(如铁)反应,产生高活性的下游ROS。在反应途径和动力学的背景下,消除过量的H2O2对于最大限度地减少下游ROS的形成,防止氧化损伤,避免免疫致病是至关重要的。一直以来,维生素C是临床治疗中常用的抗氧化剂,但由于反应效率低其在治疗脓毒症的效果中存在差异。
过氧化氢酶(Catalase CAT)是肝脏、红细胞和肺泡上皮细胞中普遍存在的最丰富的抗氧化酶,是分解H2O2最有效的催化剂。一个CAT分子可以在1秒内分解107个H2O2分子,可最大程度减少下游ROS的形成,抑制过度的炎症反应,减轻继发性的组织器官损害,改善患者的预后。然而,CAT通常表现出较差的稳定性和较短的半衰期,限制其在临床上应用。
发明内容
本发明的目的是针对现有技术存在的缺陷,提出一种纳米复合物、其制备方法及应用,为脓毒症药物的研究提供新的途径。
本发明通过以下技术方案解决技术问题: 本发明首先提供一种纳米复合物,该纳米复合物由mPEG-NHS 20K修饰过氧化氢酶形成。
为了探索CAT的治疗用途,本发明使用FDA批准的可在体内注射药用的合成聚合物PEG修饰CAT,增强CAT药物的稳定性,细胞穿透性及体内循环时间,达到消除细胞内过量H2O2来治疗脓毒症的目的。
具体方法如下:
将过氧化氢酶溶于pH8.0,0.2M的磷酸盐缓冲液中,缓慢加入溶解于二甲基亚砜中的PEG-NHS 20K常温反应2h,离心法除去未反应的聚乙二醇并更换为pH7.4的磷酸盐缓冲溶液。,得到纳米复合物。
其中,聚乙二醇与过氧化氢酶的摩尔比为 500:1。
过氧化氢酶是机体抗氧化体系的一种关键酶,是肝脏、红细胞和肺泡上皮细胞中普遍存在的最丰富的抗氧化酶,可高效分解生理和病理条件下机体产生的过氧化氢,减轻由活性氧(ROS)对组织造成的氧化损伤,抑制过度的炎症反应。由于外源过氧化氢酶在血液循环中迅速被代谢失活,血浆半衰期极短。此外,外源过氧化氢酶对储存环境变化比较敏感,容易变性失活,不稳定。这些因素限制了过氧化氢酶在药理学研究和临床上的应用。本发明选用PEG-20K作为修饰剂对外源过氧化氢进行结构修饰,通过对修饰前后的过氧化氢酶的酶学性质进行比较,PEG修饰后的过氧化氢酶保留了原有的高活力。由于PEG的屏蔽作用,PEG修饰后的过氧化氢酶复合物表面的电性接近中性。体外研究表明,过氧化氢酶可以下调激活的白细胞(WBC)产生的TNF-α,IL-1β,IL-6,IL-10,保护健康的肺上皮细胞免受激活的白细胞的损伤,实验结果提示,过氧化氢酶有可能作为一种免疫调节剂用于治疗炎症反应。体内研究表明,静脉内给药后,PEG修饰的过氧化氢酶与未修饰的天然过氧化氢酶相比,在小鼠体内有更长的循环时间。在体内通过催化H2O2分解为无毒的H2O和O2,降低细胞内ROS水平,降低血清中炎症因子水平,减缓脓毒症病理过程,减少组织损伤,最终降低小鼠的死亡率。实验结果提示,PEG化的过氧化氢酶具备进一步研究开发为与ROS相关疾病的治疗。
本发明通过mPEG-NHS 20K修饰过氧化氢酶(Catalase CAT)获到高活力保留的CAT-PEG,具有良好的水溶性,体内长循环性及生物相容性。与天然过氧化氢酶相比,更有助于缓解细胞内ROS应激,调节细胞因子的产生,减轻由ROS引起的损伤。为脓毒症的药物应用提供新的途径。
附图说明
图1 CAT与CAT-PEG的HPLC图谱。
图2 CAT与CAT-PEG的粒径表征图。
图3 CAT与CAT-PEG的表面电荷图。
图4 CAT-PEG的TEM图。
图5 CAT与CAT-PEG的活性比较图。
图6 经LPS激活的WBC和不同浓度的CAT-PEG培养的HPAEpiC培养液中TNF-α、IL-1β、IL-6和IL-10的浓度图。
图7 小鼠静脉注射CAT, CAT-PEG后血液中CAT活性随时间变化曲线。
具体实施方式
实施例1
本实施例通过以下方法制备纳米复合物:
1, 过氧化氢酶的PEG修饰
CAT溶于磷酸盐缓冲液(PH=8.0,0.2 M)中,缓慢加入溶解于DMSO中的PEG-NHS 20K
(1:500,n/n,CAT:PEG)常温反应2 h,离心法除去未反应的PEG并更换为PH=7.4的磷酸盐缓冲溶液。
2, 过氧化氢酶的活性测试
将制备好的CAT-PEG通过紫外分光光度法用过氧化氢酶活性检测试剂盒检测过氧化氢酶的活性。具体步骤如下:
取1mL H2O2溶液(PH=7.4,0.1 M HEPES缓冲液,H2O2浓度:0.03% w/v)于1 mL石英比色皿中,再加入35 µL样本,混匀5 s;室温下立即测定240 nm下的初始吸光值A1和1 min后的吸光值A2。计算ΔA=A1-A2。根据公式CAT(U/mL)=[ΔA×V反总÷(ε×d)×106] ÷V样÷T=678×ΔA计算过氧CAT活性。
3, PEG化过氧化氢酶的表征
3.1PEG化过氧化氢酶的HPLC表征
使用安捷伦高效液相色谱仪,经BioCore SEC-300上样后用150 mM PB缓冲液为流动相进行天然过氧化物酶和PEG修饰的过氧化物酶的表征。
3.2PEG化过氧化氢酶的粒径和电位表征
取在PB溶液中透析过的CAT-PEG复合物1 mL,用Malvern Zetasizer Nano ZSE仪器进行动态光散射测试,表征纳米胶囊的粒径和zeta点位。
3.3PEG化过氧化氢酶的透射电镜表征
TEM样品的制备过程如下:首先滴加10 µL CAT-PEG溶液到喷有碳膜的TEM铜网上,并静置5min,然后用滤纸吸去多余的样品,注意不要接触到铜网,pH 7.0的1%磷钨酸溶液染色2 min后,用去离子水洗去染色剂,晾干后用于TEM观察。
4, 体外实验
为证实CAT-PEG保护HPAEpiC免受活化白细胞损伤的能力,将人肺上皮细胞(HPAEpiC)
与含1 µg/mL脂多糖(LPS)的100,000个白细胞(WBC)孵育,以激活WBC。然后分别加入终浓度为8、16和40 µg/mL的CAT-PEG,孵育24 h后通过ELISA检测细胞中的细胞因子。HPAEpiC中加入1 µg/mL LPS作为对照1,未加LPS的HPAEpiC中加入白细胞作为对照2。
5, 小鼠体内实验
5.1 小鼠饲养条件
BALB/C (SPF)雄性小鼠,4周龄,体重13-15 g,购自北京华阜康生物科技股份有限公司。饲养条件:SPF级动物实验房,恒温(22℃-25℃)、恒湿(55±5%)饲养。
5.2 PEG化过氧化氢酶的药代动力学评估
为了评估CAT-PEG在体内的药代动力学,BALB/c小鼠(4周,13-15 g,n=3)尾静脉注射5mg/kg天然过氧化氢酶或CAT-PEG,分别于注射后0.1、1、2、4、6、12、24、36、48 h采血。血清在4000 xg下离心10min从全血中分离出来。取1 mL H2O2溶液(pH = 7.4,0.1 M HEPES缓冲液,H2O2浓度:0.03%w / v)于1 mL石英比色皿中,再加入35 µL血清样本,混匀5 s;室温下立即测定240 nm下的初始吸光值A1和1 min后的吸光值A2。计算ΔA=A1-A2。根据公式CAT(U/mL)=[ΔA×V反总÷(ε×d)×106] ÷V样÷T=678×ΔA计算过氧CAT活性。
5.3 小鼠脓毒症模型的建立与治疗效果测试
(1)模型建立
将30只健康小鼠分为3组,分别为模型组,CAT给药治疗组,CAT-PEG给药治疗组。模型组尾静脉注射100 µg/kg LPS+800 µg/kgD-GalN不给予治疗。CAT给药治疗组和CAT-PEG给药治疗组在尾静脉注射100 µg/kgLPS+800 µg/kgD-GalN后再分别尾静脉注射5 mg/kg的CAT和CAT-PEG(给药前使用0.22 µm的膜进行过滤)。三组给药后,观察三组小鼠的生存情况,评价24 h内的生存率。
(2)标本留取及细胞因子测试
在给药1 2h后,麻醉小鼠,收集眼眶静脉丛血液样品,置于离心管中,室温静置1 h后血清在4000 xg下离心10min从全血中分离出来。-80℃储存待用。根据ELISA说明书进行TNF-α、IL-1β、IL-6和IL-10的检测。
6, 实验结果
图1展示了天然过氧化氢酶和经PEG修饰的过氧化氢酶的HPLC结果:由于PEG修饰的产物分子量大于未修饰酶,在凝胶色谱柱中保留时间比未修饰的酶保留时间短,首先被洗脱下来,也证明过氧化氢酶被成功修饰。如图2和图3所示,与天然过氧化氢酶(<10 nm和-6.5 mV)相比,CAT-PEG的粒径分布集中在17 nm,Zeta电位接近中性,这也为在体内有更长的循环时间提供了基础;TEM图像证实n(CAT)的平均粒径为15-20 nm(图4)。与天然过氧化氢酶相比,CAT-PEG保留了天然过氧化氢酶原有的高活性(图5)。
脓毒症时产生的内毒素刺激炎性细胞释放大量促炎细胞因子(如TNF-α、IL-1β、IL-6),同时这些炎性因子可促发宿主的固有免疫反应来对抗感染和组织损伤,在脓毒症的发展过程中起重要作用。脓毒症的严重程度、病死率与较高的炎性细胞因子水平直接相关。
根据这些发现研究了人白细胞(WBC)中CAT-PEG调节细胞因子产生的能力以及CAT-PEG保护HPAEpiC免受活化白细胞损伤的能力。如图6所示,LPS激活的白细胞培养的人肺上皮细胞中细胞因子急剧增加,而加入8、16和40 µg/mL CAT-PEG孵育后明显下调了细胞中的TNF-α、IL-1β、IL-6、IL-10四种细胞因子水平。这项体外研究表明:CAT-PEG可以下调激活的白细胞产生的TNF-α、IL-1β、IL-6、IL-10,保护健康肺泡细胞免受活化白细胞的损伤,提示CAT-PEG有可能作为一种免疫调节剂用于治疗炎症反应的药物中。
在治疗方面,我们首先研究了CAT-PEG在小鼠体内的药代动力学。如图7所示CAT-PEG静脉给药后在体内循环时间比天然CAT要长的多,这种延长的循环允许CAT积聚各组织,提高CAT的药效。
除上述实施外,本发明还可以有其他实施方式。凡采用等同替换或等效变换形成的技术方案,均落在本发明要求的保护范围。
Claims (4)
1.一种纳米复合物,由mPEG-NHS 5K或20K修饰过氧化氢酶形成。
2.根据权利要求1所述纳米复合物的制备方法,其特征在于:将过氧化氢酶溶于pH8.0,0.2M的磷酸盐缓冲液中,缓慢加入溶解于二甲基亚砜中的PEG-NHS 5K-20K常温反应2-6h,得到纳米复合物。
3.根据权利要求2所述纳米复合物的制备方法,其特征在于:聚乙二醇与过氧化氢酶的摩尔比为 100-200:1PEG-NHS 5K或50-3000:1PEG-NHS 20K。
4.根据权利要求1所述纳米复合物在制备脓毒症药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111262094 | 2021-10-28 | ||
CN2021112620946 | 2021-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114767839A true CN114767839A (zh) | 2022-07-22 |
Family
ID=82426464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210350622.1A Pending CN114767839A (zh) | 2021-10-28 | 2022-04-02 | 一种纳米复合物及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114767839A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772789A (zh) * | 2011-05-10 | 2012-11-14 | 复旦大学 | Peg修饰的重组人源过氧化氢酶的药物用途 |
CN103781475A (zh) * | 2011-07-06 | 2014-05-07 | 加利福尼亚大学董事会 | 利用纳米胶囊口服递送酶以实现酒精或有毒代谢物的靶向代谢 |
RU2552340C1 (ru) * | 2013-11-29 | 2015-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Наночастицы антиоксидантного фермента супероксиддисмутазы в виде полиэлектролитного комплекса состава фермент-поликатион-полианион и способ их получения |
US20170028076A1 (en) * | 2013-12-27 | 2017-02-02 | Korea Advanced Institute Of Science And Technology | Bilirubin nanoparticle, use thereof, and preparation method therefor |
CN109419782A (zh) * | 2017-08-30 | 2019-03-05 | 复旦大学 | 一种提高酶类药物稳定性的纳米制剂及其制备方法和用途 |
CN111773245A (zh) * | 2020-06-24 | 2020-10-16 | 东南大学 | 一种复合纳米酶及其制备方法与应用 |
-
2022
- 2022-04-02 CN CN202210350622.1A patent/CN114767839A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772789A (zh) * | 2011-05-10 | 2012-11-14 | 复旦大学 | Peg修饰的重组人源过氧化氢酶的药物用途 |
CN103781475A (zh) * | 2011-07-06 | 2014-05-07 | 加利福尼亚大学董事会 | 利用纳米胶囊口服递送酶以实现酒精或有毒代谢物的靶向代谢 |
RU2552340C1 (ru) * | 2013-11-29 | 2015-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Наночастицы антиоксидантного фермента супероксиддисмутазы в виде полиэлектролитного комплекса состава фермент-поликатион-полианион и способ их получения |
US20170028076A1 (en) * | 2013-12-27 | 2017-02-02 | Korea Advanced Institute Of Science And Technology | Bilirubin nanoparticle, use thereof, and preparation method therefor |
CN109419782A (zh) * | 2017-08-30 | 2019-03-05 | 复旦大学 | 一种提高酶类药物稳定性的纳米制剂及其制备方法和用途 |
CN111773245A (zh) * | 2020-06-24 | 2020-10-16 | 东南大学 | 一种复合纳米酶及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
JOÃO H P M SANTOS等: "Pegylated catalase as a potential alternative to treat vitiligo and UV induced skin damage", 《BIOORG MED CHEM》, vol. 15, no. 30, 8 December 2020 (2020-12-08), pages 1 - 10 * |
RAN YAN 等: "Enzyme Therapeutic for Ischemia and Reperfusion Injury in Organ Transplantation", 《ADV. MATER.》, vol. 34, no. 1, 7 October 2021 (2021-10-07), pages 1 - 10 * |
卢绍曾;吴剑荣;朱莉;郑志永;詹晓北;: "聚乙二醇-聚唾液酸嵌段聚合修饰尿酸酶", 生物加工过程, vol. 13, no. 02, 15 March 2015 (2015-03-15), pages 86 - 92 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220133859A1 (en) | Oral delivery of enzymes by nanocapsules for targeted metabolism of alcohol or toxic metabolites | |
CN108078958B (zh) | 一种抗肿瘤多肽纳米药物及其制备方法和应用 | |
JP4228052B2 (ja) | 水溶性ポリエン複合体 | |
JPS62255435A (ja) | 安定性タンパク質及びタンパク質の安定化法 | |
EP2751127B1 (de) | Cyclosporin-derivate | |
JP2978187B2 (ja) | 修飾スーパーオキサイドディスムターゼの製造法 | |
EP1278868A2 (en) | Novel mutated form of arginine deiminase | |
CN109320585B (zh) | 一种具有专一性抗痤疮丙酸杆菌作用及抗炎作用的短脂肽 | |
WO2018113684A1 (zh) | 富勒烯结构在制备治疗白血病的药物中的应用 | |
WO2012162490A1 (en) | Nanozyme compositions and methods of synthesis and use thereof | |
WO2021168996A1 (en) | Catalase nanocapsules and methods for use | |
CN114767839A (zh) | 一种纳米复合物及应用 | |
KR101336552B1 (ko) | 전립선암 특이적 siRNA 전달체 | |
CN113121642A (zh) | 自组装多肽、氧化还原响应多肽水凝胶及其制备方法和应用 | |
WO2020107565A1 (zh) | 一种用于清除氧自由基的小分子蛋白质及其应用 | |
JPH02231078A (ja) | ヒアルロン酸修飾スーパーオキシドジスムターゼ | |
WO2017186779A1 (fr) | Derives amides des acides polycafeoylquiniques, procede de preparation et utilisations | |
JPH0195774A (ja) | 修飾スーパーオキサイド・ジスムターゼ | |
Wang et al. | Neutrophil-targeted Mn3O4 nanozyme treats myocardial ischemia reperfusion injury by scavenging reactive oxygen species | |
Sun et al. | Macrophage membrane-decorated MnO2 nanozyme catalyzed the scavenging of estradiol for endometriosis treatment | |
US20080020977A1 (en) | Use of Fullerenes to Oxidize Reduced Redox Proteins | |
CN116731992A (zh) | 一种PEG修饰的DhHP-6及其制备方法和用途 | |
CN114533569B (zh) | 适用于眼部皮肤的细胞穿膜肽/磷脂聚合物修饰的脂质体乳液及其制备和应用 | |
RU2783776C1 (ru) | Новый пептид и его применение | |
CN117045619A (zh) | 一种共载蜂毒溶瘤肽和腺苷a2ar受体抑制剂的脂质体-聚合物纳米粒及制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230516 Address after: No.66210, 3rd floor, Pudong Free Trade Zone, Shanghai, China Applicant after: Shanghai Bajiuba Biotechnology Co.,Ltd. Address before: 210000 room 10-2102, yunjingwan, Haicheng, Shuangzha street, Jianye District, Nanjing City, Jiangsu Province Applicant before: Yan Ran |